Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCE1m6-NSCs and Irinotecan in Recurrent High-Grade Gliomas
NCT02192359Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Apr 2016
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboxylesterase-expressing allogeneic neural stem cells in glioma, sponsored by City of Hope. Primary endpoints: Number of Participants Experiencing a Dose-limiting Toxicity at 28 days, Number of Participants With Grade 3 or Higher Toxicity Profile Attributed to NSCs up to 5 years and 1 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
carboxylesterase-expressing allogeneic neural stem cells
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02192359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192359.